The Wegovy pill is a genuinely new product, not a rebrand. FDA approved once-daily oral semaglutide 25 mg on December 22, 2025 as the first oral GLP-1 medicine for obesity in the United States, and Novo Nordisk launched it in early January 2026. It is not the Wegovy injection pen, and it is not Rybelsus, which is oral semaglutide at 7 mg or 14 mg approved for type 2 diabetes.
That distinction is worth real money, because the tablets are priced well below the pens and well below every other branded GLP-1 on the market. Novo Nordisk’s published self-pay price starts at $149 a month against a $1,349.02 list price for the identical bottle. This guide lays out what Wegovy pills cost without insurance at every dose, verified on Novo Nordisk’s own NovoCare and Wegovy pages plus the federal TrumpRx site on September 2, 2026.
What Do Wegovy Pills Cost Without Insurance?
Program prices below come from Novo Nordisk’s own pricing pages. Retail figures come from SingleCare’s live Wegovy page, updated September 2, 2026. One month always means one bottle of 30 tablets.
| Option | Low | Average | High |
|---|---|---|---|
| Wegovy tablets, NovoCare self-pay | $149/mo (1.5 mg) | $199/mo (4 mg) | $299/mo (9 mg and 25 mg) |
| Wegovy tablets, commercial insurance plus savings card | $25/mo | $25/mo | Savings capped at $100/mo |
| Wegovy tablets, retail counter with a discount card | about $1,086 per 30 tablets | about $1,086 per 30 tablets | varies by pharmacy |
| Wegovy tablets, retail cash with no card | $1,819.86 per 30 tablets | $1,819.86 per 30 tablets | $1,819.86 per 30 tablets |
| Novo Nordisk list price | - | $1,349.02 per 30-tablet package | - |
The spread between the first row and the last three is the entire story. Every meaningful decision a cash payer makes on this drug is about which door they walk through, not which pharmacy they pick.
The dose ladder is the price ladder
This is where most coverage of the Wegovy pill gets sloppy. The $149 headline is the price of the 1.5 mg starting dose only. Novo Nordisk’s footnote on the NovoCare pricing page is explicit: patients pay $149 for each month of 1.5 mg, $199 per month for 4 mg, and $299 per month for 9 mg and 25 mg.
The dose that carries the approval is 25 mg. The OASIS 4 trial that supported it ran a 12-week dose escalation to 25 mg once daily, and that is the dose Novo Nordisk reported delivering about 17% average weight loss at 64 weeks if all patients stayed on treatment. So if your prescriber titrates you to the studied maintenance dose, your real long-term number is $299 a month, not $149.
Budget for the ladder, not the first rung. Four months at $149, a stretch at $199, and then $299 a month indefinitely is a truer picture of the first year than the number in the headlines.
The August 31, 2026 price change on the 4 mg dose
The 4 mg tablet was also $149 until recently. Both Novo Nordisk’s NovoCare pricing page and the TrumpRx coupon page carry the same footnote: the $149 offer on 4 mg was available only until August 31, 2026, after which the price is $199 per month. Since that date has now passed, the 4 mg dose costs $199.
The TrumpRx page still banners “Pay $149 for each month of Wegovy 1.5 mg and 4 mg tablets” above that footnote, which is easy to misread. Read the footnote, not the banner.
What the tablets cost at an ordinary pharmacy counter
If you skip the manufacturer channel entirely, you pay something near list. SingleCare’s Wegovy page on September 2, 2026 shows an average retail cash price of $1,819.86 for 30 tablets of the 1.5 mg strength, dropping to about $1,086.35 with a SingleCare card.
Two caveats on that. First, the sources disagree: SingleCare’s average retail figure sits about $470 above Novo Nordisk’s own $1,349.02 list price for the same package, which is normal for retail markup over wholesale acquisition cost but means the “real” counter price sits somewhere in that band depending on the pharmacy. Second, a single named chain’s card price on a coupon site moves between visits, so treat any per-pharmacy row as an illustration of the spread rather than a price you can hold anyone to.
Either way, the comparison is not close. The worst self-pay price in Novo Nordisk’s program ($299) is roughly a quarter of the best coupon price at a counter.
What TrumpRx lists
TrumpRx is the federal site that publishes negotiated cash prices and hands you a coupon to present at a pharmacy. It is not itself a pharmacy. Its Wegovy Pill page on September 2, 2026 lists the drug at “78% to 89% off” against an original price of $1,349.02, which maps exactly onto Novo Nordisk’s own $149 to $299 ladder.
It costs nothing to check and it is a legitimate front door to the same discount. Our fair price checker is a useful second stop for sanity-checking any number a pharmacy quotes you.
What Drives the Price
Your dose. This is the biggest single factor inside the program, worth $150 a month between the bottom and top rungs.
Which channel you buy through. The $149 to $299 pricing exists inside Novo Nordisk’s self-pay program and its participating partner pharmacies. Handing a paper prescription to a random pharmacy with no card and no program is how you end up near $1,800.
Which oral semaglutide you were actually prescribed. Three exist: the Wegovy pill (25 mg, weight management), the Ozempic pill, and Rybelsus (7 mg and 14 mg, type 2 diabetes). They have different price structures and different programs, and a prescription for one does not unlock the other’s price.
Insurance status, in both directions. The $25 savings card requires commercial insurance that covers the drug, and savings are capped at $100 a month. Government beneficiaries are excluded from the card. Self-pay pricing, by contrast, is open to anyone paying outside insurance.
Published end dates. Novo Nordisk attaches expiration dates to its promotional tiers and has moved them repeatedly. The 4 mg tablet’s $149 price already expired. Recheck before every refill rather than assuming last month’s number holds.
Cash Price vs. Insurance
Coverage for weight-management drugs is the thinnest part of the GLP-1 market. Insurers restrict by indication rather than by molecule, which is why the same active ingredient is routinely covered for diabetes and excluded for obesity. If your plan is one of the ones that excludes it, the self-pay price is not a fallback, it is your actual price.
If your commercial plan does cover the tablets, use the savings card. Novo Nordisk’s terms let eligible commercially insured patients pay as little as $25 per month, subject to a maximum savings of $100 per month, with one month defined as one bottle of 30 tablets. Government beneficiaries are excluded.
One tradeoff worth understanding before you choose: Novo Nordisk states plainly that if you take the self-pay route, the prescription is processed outside your insurance, will not count toward any deductible, and cannot be applied to your out-of-pocket maximum. On a high-deductible plan early in the year that is often still the right call, because $149 to $299 beats paying a four-figure negotiated price toward a deductible. Run the math across the full year rather than one month.
What About Compounded Semaglutide?
This is the question the $149 price mostly answers on its own, but the legal picture matters too.
FDA determined in February 2025 that the semaglutide injection shortage was resolved, which ended the window in which compounders could make copies of a commercially available drug. As of the agency’s April 1, 2026 compounding update, semaglutide appears on neither the 503B bulks list nor FDA’s drug shortage list, and the agency reiterated that a compounded product with the same active ingredient, in the same or an easily substitutable strength, by the same route of administration, is treated as essentially a copy.
FDA went further on February 6, 2026, announcing it intends to restrict GLP-1 active pharmaceutical ingredients destined for non-FDA-approved compounded drugs that are being mass-marketed as alternatives to approved products. In the same statement the agency said sellers cannot claim compounded products are generic versions of, or the same as, FDA-approved drugs, and cannot claim they are clinically proven.
The practical consumer point is simpler than the regulatory one. At $149 to $299 a month for an FDA-approved, US-manufactured tablet with a published price, the compounding route no longer has an obvious cost advantage to trade against the quality and legal uncertainty. Whether any GLP-1 is right for you is a conversation for your prescriber, not a budgeting exercise.
How to Pay Less
-
Buy through the manufacturer’s channel. Have your prescriber send the prescription to NovoCare Pharmacy rather than your usual store. Shipping is free, FSA and HSA cards are accepted, and the price difference against a retail counter is roughly $800 to $1,600 a month.
-
Pull the TrumpRx coupon before you fill. The federal site publishes the same discount as a coupon you present at a participating retail pharmacy, which is useful if you would rather pick up locally than wait on delivery.
-
Ask what your dose actually costs, not what the ad says. The gap between the 1.5 mg and 25 mg price is $150 a month. Confirm the number for the strength on your prescription before your first fill.
-
Price the pill against the pen and the other brands. The Wegovy injection runs $349 a month self-pay, so the tablets undercut it at every dose. Compare the whole field in our GLP-1 cost guide, and see tirzepatide and Ozempic for the alternatives. If a GLP-1 is out of reach entirely, the older oral options like Qsymia and phentermine cost a fraction as much.
-
Handle the prescribing visit cheaply. This is a prescription drug with ongoing follow-up. A free or sliding-scale clinic can cover the visits at little or no cost, and a cash-pay doctor visit typically runs $50 to $150.
-
Use discount cards for everything else on your list. Coupon cards rarely beat a manufacturer program on a brand-new brand drug, but they routinely cut the rest of a prescription list to a few dollars. Our comparison of GoodRx vs. SingleCare shows how to check both in about two minutes. And if a lab or clinic bill from the workup lands harder than expected, our guide to negotiating medical bills covers what to say.
The Bottom Line
Budget $149 a month while you are starting on 1.5 mg, $199 on 4 mg, and $299 a month once you reach the 9 mg or 25 mg maintenance doses. Those are Novo Nordisk’s own published self-pay prices, re-checked on its pages and on TrumpRx on September 2, 2026, and no insurance is required to get them.
The one mistake that costs real money is filling this at a retail counter outside the program, where the same 30-tablet bottle runs roughly $1,086 with a card and $1,819.86 without one. Check the manufacturer channel first, every single refill.